抗C5a抗体(韦洛利单抗)治疗重症有创机械通气COVID-19患者(PANAMO):多中心、双盲、随机、安慰剂对照3期试验
PANAMO是一项在9个国家46家医院开展的多中心、双盲、随机、安慰剂对照3期试验,纳入368例有创机械通气(首次输注时插管不超过48小时)、PaO2/FiO2 60-200 mmHg、14天内确诊SARS-CoV-2感染(任何变异株)的成人患者,1:1随机接受标准治疗+韦洛利单抗800 mg静脉注射(最多6剂,第1、2、4、8、15、22天)或标准治疗+安慰剂。主要终点28天全因死亡率在主分析(按中心分层)中为韦洛利单抗组32%(95%CI 25-39)vs 安慰剂组42%(35-49),HR 0.73(95%CI 0.50-1.06),p=0.094;预设的未按中心分层分析中韦洛利单抗显著降低28天全因死亡率(HR 0.67,95%CI 0.48-0.96;p=0.027)。作者认为韦洛利单抗可考虑作为该类患者的附加治疗,并需进一步研究韦洛利单抗和C5a在其他引起急性呼吸窘迫综合征的病毒感染中的作用。
要点
- 主分析(按中心分层)28天全因死亡率韦洛利单抗组32%(95%CI 25-39)vs 安慰剂组42%(35-49),HR 0.73(95%CI 0.50-1.06),p=0.094,未达统计学显著。
- 预设的未按中心分层分析中,韦洛利单抗显著降低28天全因死亡率:HR 0.67(95%CI 0.48-0.96),p=0.027。
- 韦洛利单抗用法为800 mg静脉注射,最多6剂,分别于第1、2、4、8、15、22天给药,出院后不再继续。
- 纳入标准为有创机械通气且首次输注时插管不超过48小时、PaO2/FiO2 60-200 mmHg、14天内确诊SARS-CoV-2感染(任何变异株)的成人。
- 安全性分析集中严重治疗中出现的不良事件:韦洛利单抗组103/175(59%)vs 安慰剂组120/189(63%)。
适用人群与场景
- 年龄18岁及以上、正在接受有创机械通气且首次输注时插管不超过48小时、PaO2/FiO2比值60-200 mmHg、过去14天内确诊SARS-CoV-2感染(任何变异株)的患者。
- 研究在荷兰、德国、法国、比利时、俄罗斯、巴西、秘鲁、墨西哥和南非的46家医院开展。
诊断标准与关键阈值
- 纳入标准:年龄18岁及以上;正在接受有创机械通气,首次输注时插管不超过48小时;PaO2/FiO2比值60-200 mmHg;过去14天内确诊SARS-CoV-2感染(任何变异株)。
处置流程与药物剂量
- 韦洛利单抗800 mg静脉注射,最多6剂,分别于第1、2、4、8、15、22天给药;出院后不再继续治疗。
- 所有患者同时接受标准治疗。
研究设计与关键结果
- 研究类型:多中心、双盲、随机、安慰剂对照3期试验;2020年10月1日至2021年10月4日纳入368例患者进入意向性分析(全分析集;韦洛利单抗组177例,安慰剂组191例)。
- 韦洛利单抗组1例因随机分配错误且未接受治疗被排除出主要分析;至少接受一剂研究治疗者364例(99%)(安全性分析集)。
- 28天内死亡:韦洛利单抗组54/177(31%),安慰剂组77/191(40%)。
- 主要终点28天全因死亡率:韦洛利单抗组32%(95%CI 25-39)vs 安慰剂组42%(35-49),HR 0.73(95%CI 0.50-1.06),p=0.094。
- 预设的未按中心分层分析:韦洛利单抗显著降低28天全因死亡率(HR 0.67,95%CI 0.48-0.96;p=0.027)。
- 最常见治疗中出现的不良事件:急性肾损伤(韦洛利单抗组35/175(20%)vs 安慰剂组40/189(21%))、肺炎(38/175(22%)vs 26/189(14%))、感染性休克(24/175(14%)vs 31/189(16%))。
- 严重治疗中出现的不良事件:韦洛利单抗组103/175(59%)vs 安慰剂组120/189(63%)。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机、安慰剂对照3期试验。
- 作者结论:在标准治疗基础上,韦洛利单抗改善有创机械通气COVID-19患者的生存并显著降低死亡率;韦洛利单抗可考虑作为该类患者的附加治疗,仍需进一步研究韦洛利单抗和C5a在其他引起急性呼吸窘迫综合征的病毒感染中的作用。
对床旁实践的改变
- 作者认为,韦洛利单抗可考虑作为有创机械通气COVID-19患者(插管不超过48小时、PaO2/FiO2 60-200 mmHg)在标准治疗基础上的附加治疗。
- 作者指出,仍需进一步研究韦洛利单抗和C5a在其他引起急性呼吸窘迫综合征的病毒感染中的作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to determine whether vilobelimab in addition to standard of care improves survival outcomes in this patient population.
METHODS: This randomised, double-blind, placebo-controlled, multicentre phase 3 trial was performed at 46 hospitals in the Netherlands, Germany, France, Belgium, Russia, Brazil, Peru, Mexico, and South Africa. Participants aged 18 years or older who were receiving invasive mechanical ventilation, but not more than 48 h after intubation at time of first infusion, had a PaO2/FiO2 ratio of 60-200 mm Hg, and a confirmed SARS-CoV-2 infection with any variant in the past 14 days were eligible for this study. Eligible patients were randomly assigned (1:1) to receive standard of care and vilobelimab at a dose of 800 mg intravenously for a maximum of six doses (days 1, 2, 4, 8, 15, and 22) or standard of care and a matching placebo using permuted block randomisation. Treatment was not continued after hospital discharge. Participants, caregivers, and assessors were masked to group assignment. The primary outcome was defined as all-cause mortality at 28 days in the full analysis set (defined as all randomly assigned participants regardless of whether a patient started treatment, excluding patients randomly assigned in error) and measured using Kaplan-Meier analysis. Safety analyses included all patients who had received at least one infusion of either vilobelimab or placebo. This study is registered with ClinicalTrials.gov, NCT04333420.
FINDINGS: From Oct 1, 2020, to Oct 4, 2021, we included 368 patients in the ITT analysis (full analysis set; 177 in the vilobelimab group and 191 in the placebo group). One patient in the vilobelimab group was excluded from the primary analysis due to random assignment in error without treatment. At least one dose of study treatment was given to 364 (99%) patients (safety analysis set). 54 patients (31%) of 177 in the vilobelimab group and 77 patients (40%) of 191 in the placebo group died in the first 28 days. The all-cause mortality rate at 28 days was 32% (95% CI 25-39) in the vilobelimab group and 42% (35-49) in the placebo group (hazard ratio 0·73, 95% CI 0·50-1·06; p=0·094). In the predefined analysis without site-stratification, vilobelimab significantly reduced all-cause mortality at 28 days (HR 0·67, 95% CI 0·48-0·96; p=0·027). The most common TEAEs were acute kidney injury (35 [20%] of 175 in the vilobelimab group vs 40 [21%] of 189 in the placebo), pneumonia (38 [22%] vs 26 [14%]), and septic shock (24 [14%] vs 31 [16%]). Serious treatment-emergent adverse events were reported in 103 (59%) of 175 patients in the vilobelimab group versus 120 (63%) of 189 in the placebo group.
INTERPRETATION: In addition to standard of care, vilobelimab improves survival of invasive mechanically ventilated patients with COVID-19 and leads to a significant decrease in mortality. Vilobelimab could be considered as an additional therapy for patients in this setting and further research is needed on the role of vilobelimab and C5a in other acute respiratory distress syndrome-causing viral infections.
FUNDING: InflaRx and the German Federal Government.
参考来源
- Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022. PMID: 36087611. doi:10.1016/S2213-2600(22)00297-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。